Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Peter Bross(Center for Drug Evaluation and Research), Richard Pazdur(United States Food and Drug Administration), L V Kieffer, Sandip Kumar Roy, Atiqur Rahman(Jamia Millia Islamia), Xi Chen(University of Science and Technology of China), Gang Chen(Fudan University), R N Sridhara, Eamon Duffy(Auckland City Hospital), Julie Beitz, Grant Williams
PubMed
June 1, 2001
Cited by 861
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome
|The Oncologist|2018|880
Enrollment of Elderly Patients in Clinical Trials for Cancer Drug Registration: A 7-Year Experience by the US Food and Drug Administration
|Journal of Clinical Oncology|2004|735